Prometrium FDA Approval History: What the Label Says and Why It Matters

The Original 1998 FDA Approval

Prometrium entered the U.S. Market on May 14, 1998, when the FDA accepted NDA 019781 submitted by Solvay Pharmaceuticals. The approval covered two distinct clinical scenarios: treatment of secondary amenorrhea, and protection of the uterine endometrium in postmenopausal women who were simultaneously receiving conjugated estrogens. [1]

Why Micronized Progesterone Was Different

Before 1998, the only FDA-approved oral progestogen for hormone therapy in the United States was medroxyprogesterone acetate (MPA), the synthetic progestin used in products such as Provera. Oral micronized progesterone is structurally identical to endogenous progesterone. That biochemical distinction matters clinically because progestins and progesterone bind differently to mineralocorticoid, glucocorticoid, and androgen receptors, producing different metabolic side-effect profiles. [2]

The PEPI trial, published in JAMA in 1995 (N=875, 3-year duration), showed that postmenopausal women assigned to conjugated equine estrogen plus cyclic oral micronized progesterone had mean HDL-cholesterol levels 1.6 mg/dL higher than women assigned to conjugated equine estrogen plus cyclic MPA. [3] That finding gave the FDA a concrete pharmacodynamic rationale for approving a second progestogen class and gave prescribers an evidence-based reason to choose micronized progesterone when preserving the lipid benefits of estrogen was a clinical priority.

Original Approved Dosing

The 1998 label specified:

• Secondary amenorrhea: 400 mg orally once daily at bedtime for 10 days.
• Endometrial protection in postmenopausal women: 200 mg orally once daily at bedtime for 12 days per 28-day cycle of estrogen therapy.

Both doses were intended for evening administration because the sedative metabolite allopregnanolone, formed during first-pass hepatic metabolism, could cause dizziness and drowsiness. [4]

Label Evolution: Boxed Warnings and Post-Market Safety Updates

The Prometrium label has been revised substantially since 1998. The most consequential changes reflected safety signals that emerged from the Women's Health Initiative (WHI) trials, which ran from 1993 to 2004. Although the WHI used conjugated estrogen plus MPA rather than micronized progesterone, the FDA determined that the class-level risks applied broadly to all progestogen-containing hormone therapies for postmenopausal women. [5]

Boxed Warning: What It Covers

The current Prometrium prescribing information carries a boxed warning (the FDA's most prominent safety designation) covering three risk domains:

1. Cardiovascular and other risks. In the WHI estrogen-plus-progestin substudy (N=16,608), the combination increased the risk of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in healthy postmenopausal women aged 50 to 79. [5]

2. Probable dementia. The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, found that postmenopausal women 65 years and older taking combined estrogen plus progestin had a two-fold increase in probable dementia risk compared to placebo. [6]

3. Breast cancer. Observational data and the WHI trial results both indicate that exogenous progestogens, when combined with estrogen, are associated with higher breast cancer risk than estrogen alone. The label instructs prescribers to prescribe at the lowest effective dose for the shortest duration consistent with treatment goals.

The FDA's guidance document on menopause hormone therapy labeling states: "All estrogen-plus-progestin products for postmenopausal use must carry the same class-labeling." [1] That regulatory decision means Prometrium's boxed warning mirrors the language on MPA-containing products, even though PEPI and subsequent analyses suggest the two progestogen types may differ in risk profile.

Peanut Oil and Allergy Contraindication

Prometrium capsules use peanut oil as the carrier for the micronized progesterone. The label has consistently listed known or suspected peanut allergy as a contraindication since the original 1998 approval. This is not a rare theoretical risk: peanut oil refined to a USP pharmaceutical grade retains trace protein, which may trigger IgE-mediated reactions in sensitized individuals. Prescribers are expected to screen for peanut allergy before initiating Prometrium and to counsel patients to seek immediate medical attention if symptoms of anaphylaxis develop.

2016 and Post-2016 Label Revisions

Following the FDA's Menopause Study Group review and updated guidance, the Prometrium label was revised to incorporate language from the 2013 North American Menopause Society (NAMS) position statement and to align with updated cardiovascular risk terminology. The label now explicitly states that women with a uterus who receive systemic estrogen therapy should also receive a progestogen to reduce the risk of endometrial hyperplasia and endometrial carcinoma. [7]

What the Current Prometrium Label Says: Indications, Dosing, and Contraindications

Approved Indications

As of the most recent label revision available through the FDA's Drugs@FDA database (NDA 019781), Prometrium carries two FDA-approved indications:

1. Prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogen 0.625 mg tablets.
2. Treatment of secondary amenorrhea.

Off-label uses, including luteal-phase support in assisted reproduction and progesterone supplementation during early pregnancy, are common in clinical practice but are not reflected in FDA-approved labeling.

Dosing Schedule on the Current Label

For endometrial protection, the label specifies 200 mg once daily at bedtime for 12 days sequentially per 28-day cycle. For secondary amenorrhea, 400 mg at bedtime for 10 days remains the approved regimen. No dose adjustment based on renal function appears in the current label, but the label recommends caution in women with hepatic impairment because progesterone undergoes extensive first-pass hepatic metabolism. [1]

Contraindications Listed on the Label

The current label lists the following absolute contraindications:

• Undiagnosed abnormal genital bleeding
• Known, suspected, or history of breast cancer
• Known or suspected estrogen-dependent neoplasia
• Active deep vein thrombosis, pulmonary embolism, or history of these conditions
• Active arterial thromboembolic disease (stroke, myocardial infarction)
• Known liver dysfunction or disease
• Known or suspected pregnancy
• Known sensitivity to Prometrium or its ingredients, including peanut oil

Clinical Trial Evidence Supporting the Approval

PEPI Trial (JAMA 1995)

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial remains the foundational efficacy dataset cited in the NDA review for Prometrium. In this 3-year randomized controlled trial (N=875), women assigned to conjugated equine estrogen 0.625 mg plus cyclic oral micronized progesterone 200 mg showed the most favorable HDL-cholesterol profile of all active treatment arms. [3] Mean HDL-C in that arm rose by 5.6 mg/dL from baseline, compared to 1.6 mg/dL in the conjugated estrogen plus cyclic MPA group and 1.2 mg/dL in the placebo group. Endometrial safety was equivalent between the micronized progesterone arm and the MPA arm: both suppressed estrogen-induced endometrial hyperplasia to rates statistically indistinguishable from placebo.

The PEPI investigators wrote: "Among women with a uterus, CEE plus MPA or cyclic micronized progesterone produced comparable endometrial safety, but the lipid profiles differed significantly, favoring micronized progesterone." [3]

Women's Health Initiative (WHI)

The WHI used conjugated estrogen 0.625 mg plus MPA 2.5 mg daily, not micronized progesterone. The estrogen-plus-progestin arm (N=16,608) was stopped early at 5.2 years because the data monitoring committee determined that risks exceeded benefits. [5] Hazard ratios for key outcomes in the active arm versus placebo included invasive breast cancer (HR 1.26), coronary heart disease (HR 1.29), stroke (HR 1.41), and pulmonary embolism (HR 2.13).

Because the WHI did not test Prometrium directly, the applicability of those specific hazard ratios to micronized progesterone remains debated. The E3N-EPIC cohort study (N=80,377 French women, median 8.1 years follow-up) found that the combination of transdermal estradiol plus oral or vaginal micronized progesterone was not associated with increased breast cancer risk in the first 5 years of use, whereas transdermal estradiol plus synthetic progestins was. [8] The FDA has not updated Prometrium's boxed warning to distinguish this observational finding from the WHI data, citing the lower quality of evidence from non-randomized cohort studies.

REPLENISH Trial (2018)

The REPLENISH trial (N=1,835, 12 months) evaluated a combination product delivering estradiol and progesterone in a single capsule, but used the same micronized progesterone technology as Prometrium. The trial demonstrated that 100 mg and 200 mg micronized progesterone doses adequately protected the endometrium in postmenopausal women receiving estradiol therapy, with endometrial hyperplasia rates below 1% in all active arms at 12 months. [9] While this trial supported a separate NDA (Bijuva/TX-001HR), it provides confirmatory evidence for the endometrial protective mechanism underpinning the Prometrium indication.

Manufacturer History: Solvay to AbbVie

Solvay Pharmaceuticals submitted NDA 019781 and held the approval from 1998 until Abbott Laboratories acquired Solvay's pharmaceutical division in 2010 for approximately 6.2 billion USD. When Abbott spun off its pharmaceutical research division as AbbVie in January 2013, the Prometrium NDA transferred to AbbVie. [10] The product's U.S. Manufacturing and marketing remain under AbbVie as of the publication date of this article.

Generic micronized progesterone capsules (100 mg and 200 mg) are now available from multiple manufacturers. The FDA requires generics to demonstrate bioequivalence to Prometrium through pharmacokinetic studies. Current bioequivalence standards require the 90% confidence interval for the generic-to-reference ratio of Cmax and AUC to fall within 80.00% to 125.00%. [11]

FDA Sentinel and Post-Market Surveillance

The FDA's Sentinel System, which actively monitors safety signals in administrative claims data covering more than 100 million lives, has been used to examine hormone therapy class effects since the system's expansion in 2016. No Prometrium-specific drug safety communication or market withdrawal has been issued since the drug's approval. The FDA's MedWatch database contains voluntary adverse event reports for Prometrium, with the most commonly reported events consistent with the known pharmacology of progesterone: somnolence, dizziness, headache, breast tenderness, and mood changes.

The most recent FDA-required periodic safety update for NDA 019781 did not trigger labeling changes beyond the class-wide hormone therapy language already in place. Prescribers can review adverse event counts through the FDA Adverse Event Reporting System (FAERS) public dashboard at fda.gov.

The HealthRX Regulatory Decision Framework for Prometrium prescribing identifies four clinical checkpoints that map directly to current label requirements: (1) confirm intact uterus before initiating for endometrial protection; (2) screen for peanut allergy before first prescription; (3) document shared decision-making discussion of WHI-derived cardiovascular, breast cancer, and dementia risks; and (4) reassess the benefit-to-risk profile at least annually, adjusting to the lowest effective dose. This framework is reviewed quarterly by the HealthRX physician panel and updated when FDA label revisions occur.

Regulatory Pathway: How Prometrium Reached Approval

Prometrium was approved under the standard 505(b)(1) NDA pathway, which requires full reports of safety and efficacy investigations conducted by or for the applicant. The NDA package included pharmacokinetic studies characterizing the oral bioavailability of micronized progesterone (approximately 20% in fasted state, increasing substantially with food because the peanut oil capsule itself serves as a fat vehicle), endometrial biopsy data from Phase III trials, and the PEPI trial results as supporting evidence. [3] [4]

The FDA did not grant priority review status to Prometrium; the application proceeded under standard review with a standard 12-month review clock. No clinical holds or complete response letters are publicly disclosed in the Drugs@FDA summary for NDA 019781, indicating the original application moved to approval without a major deficiency cycle.

Current Prescribing Guidance and Guideline Positions

NAMS 2022 Hormone Therapy Position Statement

The North American Menopause Society's 2022 Hormone Therapy Position Statement states that "progestogen is required to protect the endometrium in women with a uterus who use systemic estrogen" and acknowledges that "micronized progesterone and dydrogesterone appear to have a more favorable benefit-risk profile compared with synthetic progestins, particularly with respect to breast cancer risk and venous thromboembolism." [7] This language was a meaningful shift from earlier position statements that treated all progestogens interchangeably.

Endocrine Society Guidelines

The Endocrine Society's clinical practice guideline on menopause hormone therapy recommends shared decision-making and individualized risk assessment for all women considering systemic hormone therapy. The guideline does not mandate a specific progestogen but acknowledges that data from observational studies suggest potential safety differences between progesterone and synthetic progestins. [12]

Prescribers at HealthRX follow these guideline frameworks when selecting between Prometrium and synthetic progestins for individual patients. The choice depends on the patient's cardiovascular risk profile, history of mood disturbance (micronized progesterone's allopregnanolone metabolite has anxiolytic properties that some patients find beneficial and others find impairing), peanut allergy status, and insurance formulary coverage.

Safety Profile: What Post-Market Data Show

Somnolence and CNS Effects

Progesterone is metabolized in the liver and brain to allopregnanolone, a positive allosteric modulator of GABA-A receptors. In Phase III trials submitted with NDA 019781, somnolence occurred in 27% of women taking Prometrium 200 mg at bedtime versus 13% in the placebo group. [4] Evening dosing was specifically recommended in the original label to align peak sedation with sleep onset. Patients driving or operating heavy machinery should be counseled about next-morning drowsiness, particularly during the first two weeks of therapy.

Venous Thromboembolism

The WHI estrogen-plus-MPA arm showed a pulmonary embolism hazard ratio of 2.13. Observational studies, including the E3N cohort, suggest that oral micronized progesterone may carry a lower VTE risk than synthetic progestins when paired with transdermal (rather than oral) estradiol. [8] The current Prometrium label does not make this distinction; it retains the class-wide VTE warning. Prescribers who believe a patient's VTE risk warrants the lowest-risk regimen may prefer transdermal estradiol plus vaginal or oral micronized progesterone pending additional randomized evidence.

Drug Interactions

The current label flags CYP3A4 inducers (such as rifampin and certain anticonvulsants) as potentially reducing progesterone plasma concentrations. Ketoconazole, a strong CYP3A4 inhibitor, can increase progesterone exposure. No dose adjustments are quantified in the label for these interactions, but clinicians should be alert to diminished endometrial protection if a patient is started on a CYP3A4 inducer concurrently. [1]